Argus lowered the firm’s price target on Medtronic (MDT) to $105 from $120 to reflect the company’s below-consensus FY26 EPS guide that accounts the impact of tariffs but keeps a Buy rating on the shares longer term. The firm is positive on the company’s decision to spin off its Diabetes business that will allow it to focus on its businesses – Cardiovascular, Neuroscience and Medical Surgical – that have higher margins and a combined global addressable market of nearly $100B, the analyst tells investors in a research note. Medtronic’s Hugo robotic surgical system, available in more than 30 countries worldwide, is also advancing through FDA review process, and Argus expects a U.S. launch by 2026, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue